Related Experiment Video

Updated: Oct 26, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.6K

Natural STAT3 inhibitors: A mini perspective

Zhuo Wang1, Chunngai Hui2, Yusheng Xie3

  • 1Southern University of Science and Technology, School of Medicine, Shenzhen 518055, People's Republic of China.

Bioorganic Chemistry
|August 1, 2021
PubMed

Insights

Natural products offer promising therapeutic strategies by inhibiting Signal transducer and activator of transcription 3 (STAT3), a key oncogene in cancer. This review details natural STAT3 inhibitors, their biological profiles, and synthesis, highlighting their potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is crucial for cell proliferation and survival, with aberrant activation linked to numerous cancers.
  • STAT3 is recognized as a significant oncogene and a critical target for cancer therapy.
  • While small molecule STAT3 inhibitors are extensively studied, natural product inhibitors remain less explored.

Purpose of the Study:

  • To review the development of natural product-derived STAT3 inhibitors.
  • To detail their biological activities and chemical synthesis.
  • To discuss the current landscape and future prospects of STAT3 inhibitor research.

Main Methods:

  • Literature review focusing on natural products targeting the STAT3 pathway.
  • Analysis of biological profiles and chemical synthesis of identified natural STAT3 inhibitors.
  • Discussion of existing STAT3 inhibitors and future research directions.

Main Results:

  • Numerous natural products have been identified as STAT3 inhibitors.
  • These natural compounds exhibit diverse biological activities relevant to cancer therapy.
  • The chemical synthesis and biological profiles of these natural inhibitors are detailed.

Conclusions:

  • Natural products represent a valuable and underexplored source of STAT3 inhibitors.
  • Further research into natural STAT3 inhibitors could lead to novel cancer therapeutics.
  • Exploring the synthesis and biological mechanisms of these compounds offers significant opportunities.
Keywords:
InhibitorsJAKNatural productsSTAT3Synthesis

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.7K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
80
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
943